17,261 trials
Hematological Malignancies
Primary: Percentage of Participants With a Dose-Limiting Toxicity (DLT) — 4.8; 2.4; 0.0; 5.0 Percentage of Participants
Chronic Refractory Cough (CRC) With Non-atopic Asthma · CRC With Atopic Asthma · Unexplained Chronic Cough
Primary: Part A: Cough Frequency Per Hour, Assessed Objectively Over 24 Hours Using VitaloJAK® Cough Recorder — 14.88; 17.30; 12.61; 13.21 coughs/hour
Ovarian Cancer · Head and Neck Cancer · Non Small Cell Lung Cancer
Primary: To Assess the Efficacy of TJ004309 Combined With Atezolizumab in a Cohort of Patients With Platinum-resistant IO Naive Ovarian Carcinoma and a Separate Biomarker…
Type 1 Diabetes
Primary: Glycemic Control (HbA1c) — 9.1; 6.5; 8.5; 9.2 Percentage of HbA1c
Moderate to Severe Ulcerative Colitis
Primary: Induction Period: Percentage of Participants Who Achieved Clinical Remission at Week 14 — 11.6; 25.5; 23.3; 23.9 percentage of participants — p=0.0545
Locally Advanced Unresectable Pancreatic Adenocarcinoma · Metastatic Pancreatic Adenocarcinoma · Recurrent Pancreatic Adenocarcinoma
Primary: Weight Stability — -1.98; -5.58 Percent weight change
Hematological Malignancies
Primary: Successful Engraftment Using Cyclophosphamide Post-Transplant — 1.00; 0.93 Cumulative Probability of Engraftment
Melanoma Stage III · Melanoma Stage IV · Unresectable Melanoma
Primary: Arm 1: Objective Response Rate (ORR) — 18.0 percentage of participants — p=0.0148
Infusion Reaction · Monoclonal Antibody
Primary: Number of Participants With Standard Infusion Reactions (SIR) at Cycle 1 and During Subsequent Cycles of Monoclonal Antibody Infusion — 14; 26; 4; 35 Participants
Triple Negative Breast Neoplasms
Primary: Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs) — 32; 59; 2; 53 Participants
Friedreich Ataxia
Primary: Change in High Contrast Visual Acuity — 5.5; 0 Number of Letters Read on a Vision Board
Niemann-Pick Disease, Type C
Primary: Efficacy of Adrabetadex (VTS-270) to Reduce Plasma Levels of a Conjugated Bile Acid, Known as 5α-cholanic Acid-3β, 5α, 6β-triol N-(Carboxymethyl)-Amide — 32.6; 87.9 ng/ml
Depression, Bipolar · Depression, Unipolar · Dysthymia
Primary: Dimensional Anhedonia Rating Scale (DARS) Score — 15.75; 33.08 score on a scale
Down Syndrome · Alopecia Areata · Atopic Dermatitis / Eczema
Primary: Number of Serious Adverse Events (SAE) Definitely Related to Tofacitinib Treatment. — 0 Serious Adverse Events
Ovarian Cancer
Primary: CA-125 Response Rate — 0 Participants